Bydureon Bcise

Physical Activity, Type 2 Diabetes, Diet

Treatment

20 Active Studies for Bydureon Bcise

What is Bydureon Bcise

Exenatide

The Generic name of this drug

Treatment Summary

Exenatide is a medication used to control blood sugar levels. It works by activating the GLP-1 receptor, which increases insulin secretion, lowers glucagon secretion, and slows digestion. Exenatide was approved by the FDA in 2005.

Byetta

is the brand name

image of different drug pills on a surface

Bydureon Bcise Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Byetta

Exenatide

2005

10

Effectiveness

How Bydureon Bcise Affects Patients

Exenatide helps the body to better regulate its response to glucose. This means when glucose is present, insulin is released in the right amount and glucagon is released in a lower amount. During hypoglycemia, the normal amount of glucagon is still released. Additionally, exenatide slows down how quickly the stomach empties, leading to a slower and more controlled release of glucose into the body. These effects help to prevent both high and low blood sugar levels.

How Bydureon Bcise works in the body

Exenatide is a drug that helps control blood sugar levels. It does this by activating a certain receptor in the body, which then increases the production of insulin and decreases the production of glucagon. These hormones help regulate glucose levels in the body. Exenatide also slows down how quickly food leaves the stomach, which helps keep blood sugar levels steady. All of these effects work together to help prevent both high and low blood sugar.

When to interrupt dosage

The recommended quantity of Bydureon Bcise relies upon the diagnosed situation. The degree of dosage fluctuates, in light of the administration method delineated in the table below.

Condition

Dosage

Administration

Physical Activity

, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation

Subcutaneous, Injection, Injection - Subcutaneous, , Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release - Subcutaneous, Injection, powder, for suspension, extended release, Solution, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Solution - Subcutaneous, Injection, suspension, extended release - Subcutaneous, Injection, suspension, extended release, Suspension, extended release, Suspension, extended release - Subcutaneous

Type 2 Diabetes

, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation

Subcutaneous, Injection, Injection - Subcutaneous, , Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release - Subcutaneous, Injection, powder, for suspension, extended release, Solution, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Solution - Subcutaneous, Injection, suspension, extended release - Subcutaneous, Injection, suspension, extended release, Suspension, extended release, Suspension, extended release - Subcutaneous

Diet

, 0.25 mg/mL, 0.005 mg, 0.01 mg, 2.0 mg, 20.0 mg/mL, 2.0 mg/dose, 0.005 mg/pump actuation, 0.01 mg/pump actuation

Subcutaneous, Injection, Injection - Subcutaneous, , Kit, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, extended release - Subcutaneous, Injection, powder, for suspension, extended release, Solution, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Subcutaneous, Solution - Subcutaneous, Injection, suspension, extended release - Subcutaneous, Injection, suspension, extended release, Suspension, extended release, Suspension, extended release - Subcutaneous

Warnings

Bydureon Bcise Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Exenatide may interact with Pulse Frequency

There are 20 known major drug interactions with Bydureon Bcise.

Common Bydureon Bcise Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Moderate

Exenatide can cause an increase in the absorption of (R)-warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.

(S)-Warfarin

Moderate

Exenatide can cause an increase in the absorption of (S)-Warfarin resulting in an increased serum concentration and potentially a worsening of adverse effects.

2,4-thiazolidinedione

Moderate

The risk or severity of hypoglycemia can be increased when Exenatide is combined with 2,4-thiazolidinedione.

4-hydroxycoumarin

Moderate

Exenatide can cause an increase in the absorption of 4-hydroxycoumarin resulting in an increased serum concentration and potentially a worsening of adverse effects.

AICA ribonucleotide

Moderate

The risk or severity of hypoglycemia can be increased when Exenatide is combined with AICA ribonucleotide.

Bydureon Bcise Toxicity & Overdose Risk

Animal studies have shown that exenatide use during pregnancy can cause deformities in the baby’s ribs and vertebrae and slow growth. Uncontrolled high blood sugar during pregnancy has been linked to a 25% risk of miscarriage. There are no known human studies on the effects of exenatide in pregnancy and it should only be prescribed if the benefits outweigh the risks. It is not known how exenatide affects breastfed infants or pediatric patients, so the risks and benefits should be weighed carefully. Older adults may be more likely to experience side effects due to their higher risk of renal impairment or other health issues,

image of a doctor in a lab doing drug, clinical research

Bydureon Bcise Novel Uses: Which Conditions Have a Clinical Trial Featuring Bydureon Bcise?

162 active trials are currently being conducted to assess the potential of Bydureon Bcise in providing relief for Type 2 Diabetes.

Condition

Clinical Trials

Trial Phases

Type 2 Diabetes

167 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Physical Activity

24 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Bydureon Bcise Reviews: What are patients saying about Bydureon Bcise?

4.7

Patient Review

1/22/2020

Bydureon Bcise for Type 2 Diabetes Mellitus

I've been using this product for six months now, and I'm really happy with it. The pens have been working great (no problems there), and the side effects weren't too bad once my body got used to the medication. Just be careful with what you eat; if you overdo it, you'll feel pretty sick. In just 90 days, my A1C went from 9.4 to 7.2, which is amazing!

4.3

Patient Review

2/4/2019

Bydureon Bcise for Type 2 Diabetes Mellitus

After a few weeks of taking this medication, I really noticed an improvement in my condition. The injector is easy to use and painless, which is great. A common side effect that I experienced was bumps at the injection sight; however, they would go away after a couple of weeks and didn't cause any pain or discoloration.

3.3

Patient Review

5/23/2019

Bydureon Bcise for Type 2 Diabetes Mellitus

I took this drug for three months and it worked great, A1C lowered to 6.6 and I found it easy to use. Once shaken, you could see it going in, so no problem with injection. the fourth month I developed severe gas and bloating, quickly followed by nausea, vomiting and diarhhea. A miserable three days!

3.3

Patient Review

11/7/2018

Bydureon Bcise for Type 2 Diabetes Mellitus

The injector is not great. It can squirt out when you remove the cap and it can fail to penetrate the skin because of the shroud around the needle. If you can get it injected, it seems to work though.

3.3

Patient Review

6/9/2022

Bydureon Bcise for Type 2 Diabetes Mellitus

The injector is faulty; two out of the last three times I've used it, the medication hasn't been injected and has instead sprayed out. This wastes an expensive pen each time, which costs me over $100 out of pocket.

2.3

Patient Review

4/30/2019

Bydureon Bcise for Type 2 Diabetes Mellitus

I tried this for 8 weeks and saw no results.

1.7

Patient Review

10/4/2021

Bydureon Bcise for Type 2 Diabetes Mellitus

The design of this product is very poor. I have wasted three needles trying to unscrew the cap after unlocking and mixing. As soon as I try to remove the cap, the needle springs out and ejects the contents.

1.7

Patient Review

11/11/2018

Bydureon Bcise for Type 2 Diabetes Mellitus

The injector is terrible. It often squirts out when you remove the cap, and it can fail to penetrate the skin. I can't believe they released this before testing it properly.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bydureon bcise

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Bydureon BCise for?

"BYDUREON BCise is an injectable medicine that can help improve blood sugar levels in adults and children 10 years of age and older with type 2 diabetes mellitus. It should be used along with a healthy diet and exercise plan."

Answered by AI

Is Trulicity and Bydureon the same?

"Both Bydureon and Trulicity are in the same class of medication, meaning they work in the same way to improve blood sugar levels in people with type 2 diabetes."

Answered by AI

Is Bydureon considered insulin?

"No, Bydureon does not increase the amount of insulin in your body, but it does make your body release more insulin. Is Bydureon used for weight loss? No. Bydureon is not used for weight loss, even though weight loss is a common side effect."

Answered by AI

What is the difference between Bydureon pen and Bydureon BCise?

"Bydureon BCise is designed to be easy and convenient for patients to use. It only needs to be mixed for 15 seconds, compared to the Bydureon Pen which must be tapped 80 times or more to make sure the medicine is well mixed."

Answered by AI

Clinical Trials for Bydureon Bcise

Image of Centre EPIC in Montreal, Canada.

Maple Syrup for Endurance Cycling Performance

18 - 45
Male
Montreal, Canada

The goal of this clinical trial is to learn whether maple syrup can be used as a natural carbohydrate source to help trained male cyclists perform better during long-duration cycling. The study also aims to learn how different amounts of maple syrup affect energy use in the body, stomach comfort, and feelings of effort and fatigue. The main questions the study aims to answer are: * Does consuming more carbohydrate from maple syrup help participants finish a 20-kilometer cycling time trial faster? * How do different amounts of maple syrup change how the body uses carbohydrates and fats during long exercise? * Are higher amounts of maple syrup easy for participants to tolerate without stomach problems? Researchers will compare four drinks: 1. A placebo drink (a look-alike drink with no calories), 2. A drink that provides 60 grams of carbohydrate per hour, 3. A drink that provides 90 grams per hour, and 4. A drink that provides 120 grams per hour. They will compare these drinks to see whether higher carbohydrate amounts lead to better cycling performance and how each dose affects comfort and metabolism. Participants will: * Attend a screening visit that includes a health check and a glucose tolerance test. * Complete a fitness test to measure their aerobic capacity and practice the cycling tests used in the study. * Take part in four separate exercise sessions in random order. Each session includes: * Drinking one of the four study beverages during 2 hours of steady cycling, * Completing two short, all-out 6-second sprints during the ride, * Completing a 20-kilometer cycling time trial as fast as possible, * Reporting stomach symptoms and perceptions of effort, * Providing breath, blood, urine, and sweat samples so researchers can measure how their body uses fuel. All drinks will look, taste, and smell similar so participants cannot tell which one they are receiving. Meals before each session will be provided to keep conditions the same across visits. This study may help athletes and active people choose natural carbohydrate sources that support both performance and comfort during long endurance exercise. The findings may also guide future research on the use of maple syrup as a sports nutrition option.

Waitlist Available
Paid Trial

Centre EPIC

Jonathan Tremblay, PhD

Mitacs

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Faculty of Health Sciences in Winnipeg, Canada.

Saskatoon Berries for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Previous studies in the investigator's group demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Preliminary studies by the investigators in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. The investigators propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
Dietary Supplement

Faculty of Health Sciences

Have you considered Bydureon Bcise clinical trials?

We made a collection of clinical trials featuring Bydureon Bcise, we think they might fit your search criteria.
Go to Trials
Image of Central Research Associates - Flourish - PPDS in Birmingham, United States.

CX11 for Type 2 Diabetes

18 - 75
All Sexes
Birmingham, AL

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Phase 2
Waitlist Available

Central Research Associates - Flourish - PPDS (+29 Sites)

Corxel Pharmaceuticals

Have you considered Bydureon Bcise clinical trials?

We made a collection of clinical trials featuring Bydureon Bcise, we think they might fit your search criteria.
Go to Trials
Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Image of KPNC Division of Research in Pleasanton, United States.

MetSense Risk Flag for Type 2 Diabetes

18+
All Sexes
Pleasanton, CA

People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.

Waitlist Available
Has No Placebo

KPNC Division of Research

Esti Iturralde, PhD

Have you considered Bydureon Bcise clinical trials?

We made a collection of clinical trials featuring Bydureon Bcise, we think they might fit your search criteria.
Go to Trials